Cargando…
Neuer COVID-Impfstoff
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Medizin
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750714/ http://dx.doi.org/10.1007/s11298-022-3084-5 |
| _version_ | 1784850316658737152 |
|---|---|
| author | Bublak, Robert |
| author_facet | Bublak, Robert |
| author_sort | Bublak, Robert |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9750714 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Medizin |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97507142022-12-15 Neuer COVID-Impfstoff Bublak, Robert CME (Berl) Therapie Aktuell Springer Medizin 2022-12-15 2022 /pmc/articles/PMC9750714/ http://dx.doi.org/10.1007/s11298-022-3084-5 Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Therapie Aktuell Bublak, Robert Neuer COVID-Impfstoff |
| title | Neuer COVID-Impfstoff |
| title_full | Neuer COVID-Impfstoff |
| title_fullStr | Neuer COVID-Impfstoff |
| title_full_unstemmed | Neuer COVID-Impfstoff |
| title_short | Neuer COVID-Impfstoff |
| title_sort | neuer covid-impfstoff |
| topic | Therapie Aktuell |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750714/ http://dx.doi.org/10.1007/s11298-022-3084-5 |
| work_keys_str_mv | AT bublakrobert neuercovidimpfstoff |